BIOA Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -890.97% compared to Bioage Labs's net margin of --. Bioage Labs's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 39.54%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.2692 which suggests that it could grow by 341.77%. Given that Perspective Therapeutics has higher upside potential than Bioage Labs, analysts believe Perspective Therapeutics is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.093, suggesting its more volatile than the S&P 500 by 9.29%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are larger than Perspective Therapeutics quarterly revenues of --. Bioage Labs's net income of -$12.9M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Bioage Labs's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 22.77x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of -890.97% compared to Bioage Labs's net margin of -6.61%. Bioage Labs's return on equity of -- beat Integra Lifesciences Holdings's return on equity of -1.88%.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 39.54%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 16.17%. Given that Bioage Labs has higher upside potential than Integra Lifesciences Holdings, analysts believe Bioage Labs is more attractive than Integra Lifesciences Holdings.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.164, suggesting its more volatile than the S&P 500 by 16.396%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. Bioage Labs's net income of -$12.9M is higher than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Bioage Labs's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 0.66x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Reshape Lifesciences has a net margin of -890.97% compared to Bioage Labs's net margin of -68.98%. Bioage Labs's return on equity of -- beat Reshape Lifesciences's return on equity of -172.58%.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 39.54%. On the other hand Reshape Lifesciences has an analysts' consensus of -- which suggests that it could grow by 55669.16%. Given that Reshape Lifesciences has higher upside potential than Bioage Labs, analysts believe Reshape Lifesciences is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Reshape Lifesciences has a beta of 1.284, suggesting its more volatile than the S&P 500 by 28.358%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reshape Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Reshape Lifesciences pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are larger than Reshape Lifesciences quarterly revenues of $1.1M. Bioage Labs's net income of -$12.9M is lower than Reshape Lifesciences's net income of $1.5M. Notably, Bioage Labs's price-to-earnings ratio is -- while Reshape Lifesciences's PE ratio is 0.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 0.01x for Reshape Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of -890.97% compared to Bioage Labs's net margin of -30.29%. Bioage Labs's return on equity of -- beat Treace Medical Concepts's return on equity of -47.17%.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 39.54%. On the other hand Treace Medical Concepts has an analysts' consensus of $9.73 which suggests that it could grow by 64.89%. Given that Treace Medical Concepts has higher upside potential than Bioage Labs, analysts believe Treace Medical Concepts is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are smaller than Treace Medical Concepts quarterly revenues of $52.6M. Bioage Labs's net income of -$12.9M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, Bioage Labs's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 1.74x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.